# A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-s

Source: https://onco.cc/trials/nct06348199/  
OnCo record `nct06348199` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Samsung Bioepis Co., Ltd., active and no longer recruiting.

## Summary

A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT06348199 by Samsung Bioepis Co., Ltd., with 555 participants enrolled, started 2024-03-12 and due to reach its primary completion in 2026-03-10. Interventions recorded: SB27, Keytruda. Conditions listed: Non-small Cell Lung Cancer Stage IV. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06348199
- Phase: 3
- Setting: A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 (Proposed Pembrolizumab Biosimilar) and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
- Sponsor: Samsung Bioepis Co., Ltd.
- Enrolled: 555

## Sources

- ClinicalTrials.gov NCT06348199: https://clinicaltrials.gov/study/NCT06348199

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct06348199.json